{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T20:30:41Z","timestamp":1776198641578,"version":"3.50.1"},"reference-count":36,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T00:00:00Z","timestamp":1763942400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002701","name":"Ministry of Education","doi-asserted-by":"publisher","award":["RS-2023-00245246"],"award-info":[{"award-number":["RS-2023-00245246"]}],"id":[{"id":"10.13039\/501100002701","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014188","name":"Ministry of Science and ICT, South Korea","doi-asserted-by":"publisher","award":["RS-2021-NR061990"],"award-info":[{"award-number":["RS-2021-NR061990"]}],"id":[{"id":"10.13039\/501100014188","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014188","name":"Ministry of Science and ICT, South Korea","doi-asserted-by":"publisher","award":["RS-2023-00217595"],"award-info":[{"award-number":["RS-2023-00217595"]}],"id":[{"id":"10.13039\/501100014188","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014188","name":"Ministry of Science and ICT, South Korea","doi-asserted-by":"publisher","award":["RS-2025-00513751"],"award-info":[{"award-number":["RS-2025-00513751"]}],"id":[{"id":"10.13039\/501100014188","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014188","name":"Ministry of Science and ICT, South Korea","doi-asserted-by":"publisher","award":["2021-NR061990"],"award-info":[{"award-number":["2021-NR061990"]}],"id":[{"id":"10.13039\/501100014188","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003569","name":"Korea Ministry of Food and Drug Safety","doi-asserted-by":"publisher","award":["23212MFDS202"],"award-info":[{"award-number":["23212MFDS202"]}],"id":[{"id":"10.13039\/501100003569","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.neurot.2025.e00815","type":"journal-article","created":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T20:26:12Z","timestamp":1767039972000},"page":"e00815","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Repurposing dipeptidyl peptidase-4 inhibitor for Parkinson's disease prevention: A drug-target Mendelian randomization study"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5220-0950","authenticated-orcid":false,"given":"Joo-Yeon","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8658-3523","authenticated-orcid":false,"given":"Don Gueu","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9948-0160","authenticated-orcid":false,"given":"Joohon","family":"Sung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.neurot.2025.e00815_bib1","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1093\/brain\/awab015","article-title":"Beneficial effects of dipeptidyl peptidase-4 inhibitors in diabetic Parkinson's disease","volume":"144","author":"Jeong","year":"2021","journal-title":"Brain"},{"issue":"10","key":"10.1016\/j.neurot.2025.e00815_bib2","doi-asserted-by":"crossref","first-page":"3067","DOI":"10.1093\/brain\/awaa262","article-title":"Diabetes medications and risk of Parkinson's disease: a cohort study of patients with diabetes","volume":"143","author":"Brauer","year":"2020","journal-title":"Brain"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00815_bib3","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-49870-z","article-title":"Use of dipeptidyl peptidase-4 inhibitors was associated with a lower risk of Parkinson's disease in diabetic patients","volume":"13","author":"Lin","year":"2023","journal-title":"Sci Rep"},{"issue":"10103","key":"10.1016\/j.neurot.2025.e00815_bib4","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1016\/S0140-6736(17)31585-4","article-title":"Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial","volume":"390","author":"Athauda","year":"2017","journal-title":"Lancet"},{"issue":"13","key":"10.1016\/j.neurot.2025.e00815_bib5","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1056\/NEJMoa2312323","article-title":"Trial of lixisenatide in early Parkinson's disease","volume":"390","author":"Meissner","year":"2024","journal-title":"N Engl J Med"},{"issue":"10479","key":"10.1016\/j.neurot.2025.e00815_bib6","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/S0140-6736(24)02808-3","article-title":"Exenatide once a week versus placebo as a potential disease-modifying treatment for people with Parkinson's disease in the UK: a phase 3, multicentre, double-blind, parallel-group, randomised, placebo-controlled trial","volume":"405","author":"Vijiaratnam","year":"2025","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00815_bib7","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1186\/s13195-024-01573-x","article-title":"Inflammatory proteins associated with Alzheimer's disease reduced by a GLP1 receptor agonist: a post hoc analysis of the EXSCEL randomized placebo controlled trial","volume":"16","author":"Koychev","year":"2024","journal-title":"Alzheimers Res Ther"},{"issue":"3","key":"10.1016\/j.neurot.2025.e00815_bib8","doi-asserted-by":"crossref","first-page":"e650","DOI":"10.1210\/clinem\/dgae281","article-title":"Dipeptidyl peptidase 4 inhibitors vs metformin for new-onset dementia: a propensity score-matched cohort Study","volume":"110","author":"Liu","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"issue":"Pt 3","key":"10.1016\/j.neurot.2025.e00815_bib9","article-title":"Neuroprotective effects of GLP-1 receptor agonists in neurodegenerative disorders: a large-scale Propensity-matched cohort study","volume":"143","author":"Siddeeque","year":"2024","journal-title":"Int Immunopharmacol"},{"issue":"9548","key":"10.1016\/j.neurot.2025.e00815_bib10","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1016\/S0140-6736(06)69705-5","article-title":"The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes","volume":"368","author":"Drucker","year":"2006","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.neurot.2025.e00815_bib11","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1093\/eurheartj\/eht571","article-title":"Mendelian randomization of blood lipids for coronary heart disease","volume":"36","author":"Holmes","year":"2015","journal-title":"Eur Heart J"},{"issue":"9841","key":"10.1016\/j.neurot.2025.e00815_bib12","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/S0140-6736(12)60312-2","article-title":"Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study","volume":"380","author":"Voight","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.neurot.2025.e00815_bib13","series-title":"Global Health Metrics. Parkinson's disease \u2014 level 3 cause","year":"2024"},{"key":"10.1016\/j.neurot.2025.e00815_bib14","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.parkreldis.2019.10.019","article-title":"Sex differences in Parkinson's disease presentation and progression","volume":"69","author":"Abraham","year":"2019","journal-title":"Parkinsonism Relat Disorders"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00815_bib15","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1002\/mds.28312","article-title":"Differences in the presentation and progression of Parkinson's disease by sex","volume":"36","author":"Iwaki","year":"2021","journal-title":"Mov Disord"},{"issue":"9","key":"10.1016\/j.neurot.2025.e00815_bib16","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1038\/s41588-021-00913-z","article-title":"Large-scale cis- and trans-eQTL analyses identify thousands of genetic loci and polygenic scores that regulate blood gene expression","volume":"53","author":"Vosa","year":"2021","journal-title":"Nat Genet"},{"issue":"7982","key":"10.1016\/j.neurot.2025.e00815_bib17","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/s41586-023-06592-6","article-title":"Plasma proteomic associations with genetics and health in the UK Biobank","volume":"622","author":"Sun","year":"2023","journal-title":"Nature"},{"issue":"12","key":"10.1016\/j.neurot.2025.e00815_bib18","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/S1474-4422(19)30320-5","article-title":"Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies","volume":"18","author":"Nalls","year":"2019","journal-title":"Lancet Neurol"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00815_bib19","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/ana.26090","article-title":"Investigation of autosomal genetic sex differences in Parkinson's disease","volume":"90","author":"Blauwendraat","year":"2021","journal-title":"Ann Neurol"},{"issue":"7726","key":"10.1016\/j.neurot.2025.e00815_bib20","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/s41586-018-0579-z","article-title":"The UK biobank resource with deep phenotyping and genomic data","volume":"562","author":"Bycroft","year":"2018","journal-title":"Nature"},{"issue":"7944","key":"10.1016\/j.neurot.2025.e00815_bib21","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1038\/s41586-022-05473-8","article-title":"FinnGen provides genetic insights from a well-phenotyped isolated population","volume":"613","author":"Kurki","year":"2023","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.neurot.2025.e00815_bib22","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1007081","article-title":"Orienting the causal relationship between imprecisely measured traits using GWAS summary data","volume":"13","author":"Hemani","year":"2017","journal-title":"PLoS Genet"},{"issue":"16","key":"10.1016\/j.neurot.2025.e00815_bib23","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1001\/jama.2021.18236","article-title":"Strengthening the reporting of observational studies in epidemiology using mendelian randomization: the STROBE-MR statement","volume":"326","author":"Skrivankova","year":"2021","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.neurot.2025.e00815_bib24","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1093\/ije\/dyt179","article-title":"Calculating statistical power in Mendelian randomization studies","volume":"42","author":"Brion","year":"2013","journal-title":"Int J Epidemiol"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00815_bib25","doi-asserted-by":"crossref","first-page":"7496","DOI":"10.1038\/s41467-022-34732-5","article-title":"Genome-wide association study of REM sleep behavior disorder identifies polygenic risk and brain expression effects","volume":"13","author":"Krohn","year":"2022","journal-title":"Nat Commun"},{"issue":"6509","key":"10.1016\/j.neurot.2025.e00815_bib26","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1126\/science.aaz1776","article-title":"The GTEx consortium atlas of genetic regulatory effects across human tissues","volume":"369","author":"Consortium","year":"2020","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.neurot.2025.e00815_bib27","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1016\/j.cell.2018.10.022","article-title":"Impact of genetic polymorphisms on human immune cell gene expression","volume":"175","author":"Schmiedel","year":"2018","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.neurot.2025.e00815_bib28","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1038\/s41588-022-01058-3","article-title":"Multi-ancestry genetic study of type 2 diabetes highlights the power of diverse populations for discovery and translation","volume":"54","author":"Mahajan","year":"2022","journal-title":"Nat Genet"},{"issue":"9","key":"10.1016\/j.neurot.2025.e00815_bib29","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1038\/ng.2383","article-title":"Large-scale association analysis provides insights into the genetic architecture and pathophysiology of type 2 diabetes","volume":"44","author":"Morris","year":"2012","journal-title":"Nat Genet"},{"issue":"5","key":"10.1016\/j.neurot.2025.e00815_bib30","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1004383","article-title":"Bayesian test for colocalisation between pairs of genetic association studies using summary statistics","volume":"10","author":"Giambartolomei","year":"2014","journal-title":"PLoS Genet"},{"key":"10.1016\/j.neurot.2025.e00815_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2021.173862","article-title":"Parkinson's disease in women: mechanisms underlying sex differences","volume":"895","author":"Vaidya","year":"2021","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.neurot.2025.e00815_bib32","doi-asserted-by":"crossref","DOI":"10.12659\/MSM.938030","article-title":"Sex-related differences in Sitagliptin treatment in type 2 diabetes: results from the PROLOGUE trial","volume":"28","author":"Wu","year":"2022","journal-title":"Med Sci Monit"},{"key":"10.1016\/j.neurot.2025.e00815_bib34","doi-asserted-by":"crossref","DOI":"10.1136\/gutjnl-2025-334988","article-title":"DPP-4 inhibitor alleviates gut-brain axis pathology in Parkinson\u2019s disease","author":"Jeong","year":"2025","journal-title":"Gut"},{"key":"10.1016\/j.neurot.2025.e00815_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2022.105626","article-title":"Clinical and imaging evidence of brain-first and body-first Parkinson's disease","volume":"164","author":"Horsager","year":"2022","journal-title":"Neurobiol Dis"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00815_bib36","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s13098-024-01299-8","article-title":"Causal relationship between diabetes mellitus, glycemic traits and Parkinson's disease: a multivariable mendelian randomization analysis","volume":"16","author":"Wang","year":"2024","journal-title":"Diabetol Metab Syndr"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00815_bib37","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1186\/s12916-024-03700-9","article-title":"Common pitfalls in drug target Mendelian randomization and how to avoid them","volume":"22","author":"Gill","year":"2024","journal-title":"BMC Med"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747925002934?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747925002934?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T19:31:04Z","timestamp":1776195064000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747925002934"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S1878747925002934"],"URL":"https:\/\/doi.org\/10.1016\/j.neurot.2025.e00815","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Repurposing dipeptidyl peptidase-4 inhibitor for Parkinson's disease prevention: A drug-target Mendelian randomization study","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurot.2025.e00815","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of American Society for Experimental NeuroTherapeutics.","name":"copyright","label":"Copyright"}],"article-number":"e00815"}}